IMARC Group, a leading market research company, has recently releases report titled “Antipsychotic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032,” The study provides a detailed analysis of the industry, including the global antipsychotic drugs market size, share, trends, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the antipsychotic drugs market?
The global antipsychotic drugs market size reached US$ 16.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 28.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032.
Factors Affecting the Growth of the Antipsychotic Drugs Industry:
- Increasing prevalence of mental health disorders:
The rising incidence of mental health disorders such as schizophrenia, bipolar disorder, and severe depression is a primary driver of the antipsychotic drug market. According to the World Health Organization (WHO), mental health conditions are on the rise globally, with schizophrenia affecting approximately 20 million people worldwide. This increasing prevalence is partly due to better diagnostic methods and greater awareness of mental health issues, leading to more people seeking treatment. Additionally, lifestyle changes, urbanization, and socio-economic pressures contribute to the growing number of individuals experiencing mental health challenges. As the number of patients requiring treatment increases, the demand for antipsychotic medications correspondingly rises, supporting the market growth.
- Advancements in drug development:
Innovations in pharmaceutical research and development (R&D) significantly propel the antipsychotic drugs market. Over the past few decades, there has been substantial progress in understanding the pathophysiology of mental health disorders, leading to the development of more effective and safer antipsychotic medications. The introduction of second-generation antipsychotics, which generally have fewer side effects than first-generation antipsychotics, has revolutionized treatment approaches. Companies are investing heavily in research to develop drugs with improved efficacy, reduced side effects, and better patient compliance. For instance, long-acting injectable antipsychotics have been developed to address issues related to medication adherence. Continuous advancements in drug delivery systems, such as transdermal patches and novel oral formulations, are bolstering the market expansion.
- Expanding geriatric population:
The global population is aging, with the number of elderly individuals increasing at an unprecedented rate. Older adults are more susceptible to mental health disorders, including dementia-related psychosis and late-onset schizophrenia. According to the United Nations (UN), the population aged 65 and over is projected to nearly double by 2050, reaching 1.5 billion. This demographic shift is a crucial factor driving the demand for antipsychotic drugs. As the elderly population grows, so does the incidence of age-related mental health conditions, necessitating effective pharmacological interventions. Moreover, the aging population often has multiple comorbidities, requiring careful management of drug interactions and side effects, thus impelling the need for safer and more specialized antipsychotic treatments.
Request for a sample copy of this report: https://www.imarcgroup.com/antipsychotic-drugs-market/requestsample
Antipsychotic Drugs Market Report Segmentation:
Breakup By Therapeutic Class:
- First Generation
- Haldol
- Navane
- Others
- Second Generation
- Invega
- Latuda
- Seroquel
- Risperdal
- Zyprexa
- Geodon
- Others
- Third Generation
- Abilify
Second-generation drugs account for the majority of shares due to their improved efficacy and reduced side effects compared to first-generation drugs.
Breakup By Application:
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
Schizophrenia dominates the market owing to its high prevalence and requires long-term medication management.
Breakup By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Retail pharmacies hold the majority of shares due to easy accessibility and convenience for patients requiring ongoing antipsychotic medication.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position due to advanced healthcare infrastructure, high mental health awareness, and significant healthcare expenditure.
Global Antipsychotic Drugs Market Trends:
The increasing healthcare expenditure, improved access to mental health services, and rising awareness and destigmatization of mental health issues lead to higher diagnosis and treatment rates, aiding the market growth. Besides this, the integration of artificial intelligence (AI) in drug discovery, personalized medicine approaches, and government initiatives supporting mental health care. The rise of telemedicine and digital health platforms also facilitates easier access to treatment, strengthening the market demand. Furthermore, strategic collaborations and partnerships between pharmaceutical companies and research institutions, expansion of mental health insurance coverage, and increasing investments in mental health research and infrastructure by public and private sectors are contributing to the market growth.
Who are the key players operating in the industry?
The report covers the major market players including:
- AbbVie Inc.
- Alkermes plc
- Dr. Reddy’s Laboratories Ltd.
- Johnson & Johnson
- Otsuka Pharmaceutical Co. Ltd.
- Viatris Inc.
Browse the full report with TOC and list of Figures: https://www.imarcgroup.com/antipsychotic-drugs-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
